Moreover, the survival analysis on EZH2 expression in the TARGET AML dataset depicted a significant association between high expression of EZH2 and poor overall survival (P=0.00249), and event-free survival (P=0.033) (Figure 5F). This evidence concerns the gene EZH2 and acute myeloid leukemia.